A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire

Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer

Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy

A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate

A critical look at the subluxation hypothesis

A preliminary investigation of the parallelogram concept in genetic monitoring and risk estimation